{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:08Z","timestamp":1790887688459,"version":"4.1.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Sharp Dohme LLC, a subsidiary of Merck Co., Inc., Rahway, NJ, USA"},{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"crossref","award":["Support Grant P30 CA008748"],"award-info":[{"award-number":["Support Grant P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio, San Antonio, TX, USA","award":["Cancer Center Support Grant P30 CA054174"],"award-info":[{"award-number":["Cancer Center Support Grant P30 CA054174"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Zilovertamab vedotin, an antibody\u2013drug conjugate targeting receptor tyrosine kinase\u2013like orphan receptor 1 (ROR1), had manageable safety and promising antitumor activity in participants with relapsed or refractory non\u2013Hodgkin lymphomas. We evaluated zilovertamab vedotin in participants with previously treated metastatic solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>This phase 2, open-label, nonrandomized study (NCT04504916) enrolled participants with metastatic triple-negative breast cancer, hormone receptor\u2013positive breast cancer, nonsquamous non\u2013small-cell lung cancer, platinum-resistant ovarian cancer, or pancreatic cancer. Participants received zilovertamab vedotin \u22642.5 mg\/kg once every 3 weeks (Q1\/3W) or &amp;lt;1.75 mg\/kg twice every 3 weeks (Q2\/3W). The primary endpoint was objective response rate per RECIST version 1.1 by blinded independent central review. ROR1 protein expression was correlated with clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 102 participants were enrolled (Q1\/3W, n = 70; Q2\/3W, n = 32). The objective response rate was 1% [95% confidence interval (CI), 0%\u20138%] with Q1\/3W dosing (one partial response, hormone receptor\u2013positive\/HER2-negative breast cancer cohort) and 0% with Q2\/3W dosing. The median progression-free survival (95% CI) was 2.3 (2.0\u20134.1) and 1.9 (1.7\u20132.1) months, respectively; the median overall survival (95% CI) was 8.3 (5.2\u201310.3) and 5.5 (4.4\u201311.0) months, respectively. Across dosing regimens, treatment-related adverse events were reported in 85 participants (83%), most commonly fatigue (29%) and nausea (28%). Treatment-related peripheral neuropathy occurred in 8%. Treatment-related adverse events led to dose interruption\/reduction in 32 participants (31%) and permanent treatment discontinuation in 7 (7%). Tissue for ROR1 IHC was available on 17 participants, with only 3 (all nonresponders) showing ROR1 expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Zilovertamab vedotin had minimal antitumor activity, with only a single responder, and manageable safety in participants with previously treated metastatic solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Zilovertamab vedotin had minimal antitumor activity and manageable safety in participants with previously treated metastatic solid tumors of various histologic subtypes. The results suggest that further development of zilovertamab vedotin in these solid tumors is not warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0019","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T13:32:46Z","timestamp":1754400766000},"page":"1664-1673","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"Funda","family":"Meric-Bernstam","sequence":"first","affiliation":[{"name":"1Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3156-3159","authenticated-orcid":false,"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"2Hackensack University Medical Center, Hackensack, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3119-3832","authenticated-orcid":false,"given":"Enrique","family":"Sanz-Garcia","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-3009","authenticated-orcid":false,"given":"Diego","family":"Villa","sequence":"additional","affiliation":[{"name":"4University of British Columbia, BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7886-6187","authenticated-orcid":false,"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas."},{"name":"6Division of Medical Oncology, Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1149-3726","authenticated-orcid":false,"given":"Jennifer","family":"Friedmann","sequence":"additional","affiliation":[{"name":"7Gerald Bronfman Department of Oncology, Jewish General Hospital, Montreal, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-4937","authenticated-orcid":false,"given":"Fengting","family":"Yan","sequence":"additional","affiliation":[{"name":"8Swedish Cancer Institute, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2915-9325","authenticated-orcid":false,"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[{"name":"9AdventHealth Cancer Institute, Orlando, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4395-136X","authenticated-orcid":false,"given":"John","family":"Sarantopoulos","sequence":"additional","affiliation":[{"name":"10Institute for Drug Development, Mays Cancer Center at University of Texas Health San Antonio MD Anderson Cancer Center, San Antonio, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2669-5771","authenticated-orcid":false,"given":"Luis E.","family":"Raez","sequence":"additional","affiliation":[{"name":"11Memorial Cancer Institute\/Florida Atlantic University (FAU), Miami, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-3126","authenticated-orcid":false,"given":"Quincy S.","family":"Chu","sequence":"additional","affiliation":[{"name":"12Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, Edmonton, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5800-0124","authenticated-orcid":false,"given":"Maxime","family":"Ch\u00e9nard-Poirier","sequence":"additional","affiliation":[{"name":"13CHU de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2706-1342","authenticated-orcid":false,"given":"Manash S.","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"14Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3126-6495","authenticated-orcid":false,"given":"Hong","family":"Ren","sequence":"additional","affiliation":[{"name":"14Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5326-3419","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"14Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1038-8232","authenticated-orcid":false,"given":"Douglas A.","family":"Levine","sequence":"additional","affiliation":[{"name":"14Merck & Co., Inc., Rahway, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-1254","authenticated-orcid":false,"given":"Komal L.","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"15Memorial Sloan Kettering Cancer Center, New York, New York."},{"name":"16Weill Cornell Medical College, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"2025091705400726300_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/RRS-120018757","article-title":"Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans","volume":"23","author":"Yoda","year":"2003","journal-title":"J Recept Signal Transduct Res"},{"key":"2025091705400726300_bib2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/23722","article-title":"A C. elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division","volume":"400","author":"Forrester","year":"1999","journal-title":"Nature"},{"key":"2025091705400726300_bib3","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025091705400726300_bib4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"key":"2025091705400726300_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3109\/10428194.2012.731599","article-title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","volume":"54","author":"Daneshmanesh","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"2025091705400726300_bib6","doi-asserted-by":"crossref","first-page":"680834","DOI":"10.3389\/fonc.2021.680834","article-title":"Tyrosine kinase ROR1 as a target for anti-cancer therapies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"issue":"Suppl 3","key":"2025091705400726300_bib7","first-page":"2153","article-title":"Zilovertamab vedotin (MK-2140) for the treatment of non-Hodgkin lymphoma: the phase 1 dose escalation and cohort expansion Waveline-001 study of an anti-ROR1 antibody-drug conjugate","volume":"6","author":"Wang","year":"2022","journal-title":"HemaSphere"},{"key":"2025091705400726300_bib8","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"2025091705400726300_bib9","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2018-99-119447","article-title":"Development of cirmtuzumab antibody-drug conjugates (ADCs) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)","volume":"132","author":"Mian","year":"2018","journal-title":"Blood"},{"key":"2025091705400726300_bib10","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/pharmaceutics14040837","article-title":"The anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics"},{"key":"2025091705400726300_bib11","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"2025091705400726300_bib12","first-page":"33","article-title":"Targeting ROR1 using the antibody drug conjugate VLS-101 in aggressive mantle cell lymphoma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"2025091705400726300_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"Suppl 1","key":"2025091705400726300_bib14","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1182\/blood-2022-163509","article-title":"Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of zilovertamab vedotin (MK-2140) in non-Hodgkin lymphoma","volume":"140","author":"Spurgeon","year":"2022","journal-title":"Blood"},{"key":"2025091705400726300_bib15","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7531","article-title":"Zilovertamab vedotin (MK 2140) in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL): early results from the phase 2 waveLINE-004 study","volume":"41","author":"Ozcan","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091705400726300_bib16","doi-asserted-by":"crossref","first-page":"EVIDoa2100001","DOI":"10.1056\/EVIDoa2100001","article-title":"Zilovertamab vedotin targeting of ROR1 as therapy for lymphoid cancers","volume":"1","author":"Wang","year":"2022","journal-title":"NEJM Evid"},{"key":"2025091705400726300_bib17","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025091705400726300_bib18","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2025091705400726300_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025091705400726300_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025091705400726300_bib21","doi-asserted-by":"crossref","first-page":"Abstract 3029","DOI":"10.1200\/JCO.2024.42.16_suppl.3029","article-title":"Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types","volume":"42","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025091705400726300_bib22","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"2025091705400726300_bib23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"2025091705400726300_bib24","volume-title":"Tivdak (tisotumab vedotin-tftv)","author":"Seagen Inc"},{"key":"2025091705400726300_bib25","volume-title":"Polivy (polatuzumab vedotin-piiq)","author":"Genentech Inc"},{"key":"2025091705400726300_bib26","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.3390\/cancers16101874","article-title":"Heterogeneous profile of ROR1 protein expression across tumor types","volume":"16","author":"Raso","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"Suppl 16","key":"2025091705400726300_bib27","article-title":"Open-label, active-control, phase 2\/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025091705400726300_bib28","doi-asserted-by":"crossref","first-page":"TPS7589","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7589","article-title":"waveLINE-007: phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL)","volume":"41","author":"Lavie","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 16","key":"2025091705400726300_bib29","doi-asserted-by":"crossref","first-page":"TPS7595","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7595","article-title":"WaveLINE-006: a phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025091705400726300_bib30","article-title":"NBE-002 in patients with advanced solid tumors","author":"ClinicalTrials.gov"},{"key":"2025091705400726300_bib31","article-title":"A study of CS5001 in patients with advanced solid tumors and lymphomas","author":"ClinicalTrials.gov"},{"key":"2025091705400726300_bib32","first-page":"222","article-title":"Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers","volume":"4","author":"Peng","year":"2021","journal-title":"Antib Ther"},{"key":"2025091705400726300_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0019\/3638578\/crc-25-0019.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1664\/3651633\/crc-25-0019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1664\/3651633\/crc-25-0019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T09:40:16Z","timestamp":1758102016000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1664\/765343\/Phase-2-Study-of-Zilovertamab-Vedotin-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0019","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30146517","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146505","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146508","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146490","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146481","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146493","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146472","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146484","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146496","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146475","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146520","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146487","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146499","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146466","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146511","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146478","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146502","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146523","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146469","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146526","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30146514","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8039763","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}